An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia

NCT00269919 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: Risperidone Long-Acting Injectable (RLAI)

Sponsor

Janssen Korea, Ltd., Korea